Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1043]

ASCO 2019: International clinical trial of new drug for men with advanced prostate cancer yields strong result

ASCO 2019: International clinical trial of new drug for men with advanced prostate cancer yields strong result

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-sensitive prostate cancer

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone...

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal...

Stem cell differences could explain why women are more likely to develop adrenal cancer

Stem cell differences could explain why women are more likely to develop adrenal cancer

Protein that hinders advancement of prostate cancer identified

Protein that hinders advancement of prostate cancer identified

Inhibition of ribosome biogenesis as a novel approach for multi-stage cancer treatment

Inhibition of ribosome biogenesis as a novel approach for multi-stage cancer treatment

A new method to select the right treatment for advanced prostate cancer

A new method to select the right treatment for advanced prostate cancer

Test allows doctors to determine most effective treatment for women with breast cancer

Test allows doctors to determine most effective treatment for women with breast cancer

Twelve-year follow-up after peptide receptor radionuclide therapy

Twelve-year follow-up after peptide receptor radionuclide therapy

Early, hormone-driven breast cancer is less likely to recur if treated with radiotherapy

Early, hormone-driven breast cancer is less likely to recur if treated with radiotherapy

More from ecancer